1. Clinical Overview

Molecule: Cyclic heptapeptide from the melanocortin system (MC1R–MC5R)

Classification: Centrally acting sexual-arousal peptide • MC3R/MC4R agonist • Libido enhancer • Non-hormonal erectile agent • Neurovascular peptide

FDA Status: FDA-approved as Vyleesi® for Female HSDD. Compounded PT-141 widely used for both sexes.

Key Advantages Over PDE5 Inhibitors: Works on neural pathways (desire, arousal, fantasy), does not require sexual stimulation, effective for psychogenic ED, useful when PDE5i fail.

2. Mechanisms of Action

2.1 MC3R & MC4R Activation (Primary)

Stimulates hypothalamic sexual desire regions, limbic reward centers, sympathetic sexual pathways, neural NO signaling. Increased libido, heightened arousal, improved erectile quality, enhanced orgasm.

2.2 Dopaminergic Drive (Indirect)

Improves motivation, arousal psychology, desire anticipation. Safer and more targeted than apomorphine.

2.3 Erectile Function (Men)

CNS arousal signals, parasympathetic tone, cavernous smooth-muscle relaxation. Works even when PDE5i do not.

2.4 Sexual Response (Women)

Improved arousal, vaginal lubrication, desire, satisfaction. Especially helpful perimenopausal/postmenopausal.

2.5 Mood, Confidence & Reward

Increased sexual daydreaming, confidence, emotional connection, intensified anticipation.

3. Clinical Applications

3.1 Erectile Dysfunction

Psychogenic ED, vascular ED, mixed-pattern, PDE5i-nonresponsive, low libido + ED combined.

3.2 Female HSDD (FDA-Approved)

Increased desire, arousal, lubrication, orgasm intensity.

3.3 Low Libido (Men & Women)

Stress-suppressed desire, fatigue-reduced arousal, disrupted emotional connection, hormonal changes.

3.4 Sexual Performance Enhancement

High-performance individuals, couples therapy, sexual wellness programs.

3.5 Anorgasmia / Orgasm Difficulties

Difficulty reaching orgasm, delayed orgasm, reduced intensity.

4. Administration & Protocols

4.1 SC Injection (Primary)

Standard: 1.0 mg SC, 45–90 min before activity (may increase to 1.25 mg; some respond at 0.5 mg)
Enhanced: 1.25–2.0 mg SC PRN (max 2 mg)
Onset: 30–90 min | Peak: 2–4 hrs | Duration: 6–18 hrs | Lingering: 24–36 hrs
Frequency: No more than 8 doses/month

4.2 Intranasal

0.5–1.5 mg divided between nostrils. Variable potency, higher nausea, inconsistent onset. Use only if SC not acceptable.

4.3 Sensitive Patient Titration

Start 0.25–0.5 mg SC, increase by 0.25 mg increments. For women, low body weight, nausea-prone patients.

4.4 Nausea Management

Ondansetron 4–8 mg • Inject after small meal • Start very low dose.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ Melanotan-2: MT-2 primes pathways, PT-141 intensifies — most erotic synergy
+ Kisspeptin: Enhanced arousal + emotional connection + libido amplification
+ Oxytocin Acetate: Boosts bonding, intimacy, sexual communication
+ PDE5 Inhibitors: PT-141 (0.75–1 mg) + Tadalafil 5–10 mg for vascular ED
+ Melanotan-1: Sexual enhancement without deep pigmentation
+ Pinealon / DSIP: Emotional state, sleep, reduced performance anxiety

6. Clinical Decision Trees

Decision Tree 1 — Is PT-141 Appropriate?

Low libido? → YES

Psychogenic ED? → YES

Poor PDE5i response? → YES

Enhanced sexual experience? → YES

Primary anorgasmia? → PT-141 can help

Infertility therapy? → Not indicated

Pregnancy/breastfeeding? → NO (avoid)

Decision Tree 2 — Dosing Strategy

Men starting → 1 mg SC; increase 1.25–1.75 mg PRN

Women starting → 0.5–1 mg SC; increase 1–1.25 mg PRN

Sensitive patients → 0.25–0.5 mg SC

7. Integrated Archetypes

A — Couples Libido & Intimacy

PT-141 PRN + Oxytocin Acetate + Kisspeptin
Outcome: Heightened libido + emotional bonding.

B — ED Protocol (Men)

PT-141 1–1.25 mg SC + Daily Tadalafil 5 mg + Kisspeptin (optional)
Outcome: Improved erectile strength + desire.

C — Female HSDD

PT-141 0.75–1 mg SC PRN + Oxytocin + Pinealon (if cognitive fatigue)
Outcome: Improved desire & satisfaction.

D — Performance Enhancement

PT-141 ± Melanotan-2 + Adaptogens + DSIP for recovery
Outcome: Enhanced performance & recovery.

8. Expected Timeline

30–60 min: Initial libido increase
1–2 hours: Peak arousal and erectile response
6–12 hours: Sustained enhancement
24–36 hours: Residual desire boost

9. Contraindications

Absolute

Pregnancy / Breastfeeding
Uncontrolled hypertension
Severe cardiovascular disease
Known melanocortin hypersensitivity

Relative

Severe nausea disorders
Active urinary/sexual pain disorders
Psychiatric instability
Recent MI or stroke

10. Adverse Effects

Most common: nausea (dose-dependent), facial flushing, headache, mild transient BP elevation, yawning/stretching. Less common: vomiting, nasal congestion (IN), skin flushing. Rare: severe hypertension, tachycardia.

11. Monitoring

Sexual response tracking
Blood pressure (especially men)
Nausea tolerance
Libido questionnaire data
Sleep quality & mood

Legal Disclaimer

This document is provided solely for educational and informational purposes. PT-141 (Bremelanotide) and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — PT-141 (Bremelanotide)

Foundational Melanocortin

1. Cone, R. D. The central melanocortin system. Endocrine Reviews, 27(7), 736–749 (2006).

2. Wikberg, J. E. S., et al. Melanocortin receptors: pharmacology. Eur J Pharmacol, 405(1–3), 1–15 (2000).

3. Holder, J. L., & Cone, R. D. Melanocortin receptors in sexual behavior. Exp Biol Med, 228(2), 143–152 (2003).

PT-141 Development & Pharmacology

4. Hadley, M. E., & Dorr, R. T. Melanocortin peptides: Bremelanotide development. J Invest Dermatol, 124(6), 1328–1333 (2005).

5. Veverka, K. A., et al. PT-141 vs MT-2 comparative pharmacology. Clin Pharmacol Ther, 83(1), 19–28 (2008).

6. Shadiack, A. M., et al. Bremelanotide via MC4R activation. Brain Research, 1043(1–2), 28–38 (2005).

7. Diamond, L. E., et al. MC4R in sexual function. Ann N Y Acad Sci, 994, 362–375 (2003).

Male Sexual Dysfunction Trials

8. Wessells, H., et al. Bremelanotide induces erections: Phase 2. J Urol, 170(1), 1–5 (2003).

9. Aslan, M., et al. PT-141 dose-response for ED. Urology, 62(2), 234–239 (2003).

10. Wessells, H., et al. Intranasal PT-141 for ED. J Sex Med, 5(2), 301–309 (2008).

Female HSDD/FSIAD Trials

11. Kingsberg, S. A., et al. Bremelanotide RECONNECT Phase 3. Obstet Gynecol, 132(4), 845–856 (2018).

12. Clayton, A. H., et al. Bremelanotide for HSDD Phase 3. J Sex Med, 13(11), 1787–1801 (2016).

13. FDA CDER. Bremelanotide (Vyleesi) review. FDA, 2019.

14. Simon, J. A., et al. Bremelanotide in acquired HSDD. Menopause, 23(10), 1091–1098 (2016).

CNS & Behavioral

15. Pfaus, J. G., et al. Melanocortin agonists and sexual motivation. Pharmacol Biochem Behav, 90(3), 435–441 (2008).

16. Giuliano, F., et al. Central MC4R sexual pathways. Neurosci Lett, 398(1–2), 17–22 (2006).

17. Argiolas, A., & Melis, M. R. Oxytocin-melanocortin interactions. Prog Brain Res, 170, 215–228 (2008).

Metabolic & Appetite

18. Fan, W., et al. Melanocortin signaling in appetite. Nature, 385(6612), 165–168 (1997).

19. Moreno, R. J., et al. PT-141 minimal metabolic suppression vs MT-2. Peptides, 29(3), 262–267 (2008).

20. Kask, A., et al. Melanocortin-induced anorexia. Eur J Pharmacol, 398(1), 33–40 (2000).

Safety & Toxicology

21. Loland, K. H., et al. Cardiovascular safety of melanocortin agonists. Biochem Pharmacol, 67(1), 207–216 (2004).

22. FDA CDER. Bremelanotide (Vyleesi) safety review. FDA, 2019.

23. Kondou, T., et al. Melanocortin cardiac effects. Eur J Pharmacol, 396(1), 1–10 (2000).

24. Wilson, K. M., et al. Hyperpigmentation from α-MSH analogs. Dermatol Ther, 29(2), 143–151 (2016).

Psychological & Behavioral

25. Young, L. J., & Barrett, C. E. Peptide pathways in bonding and reward. Nat Rev Neurosci, 13(9), 613–625 (2012).

26. Spengler, F. B., et al. Central peptide modulation of limbic reward. Neuropsychopharmacology, 42(6), 1224–1234 (2017).

Comparative: PT-141 vs MT-1/MT-2

27. Hruby, V. J., et al. Structure-activity: MT-1, MT-2, PT-141. Peptides, 17(6), 995–1002 (1996).

28. Lammintausta, R., et al. Comparative melanocortin binding profiles. J Peptide Sci, 12(3), 139–145 (2006).